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Following Drugs:
A primary aim of the Delivering Digital Drugs project is to reveal the multiple and intercon-
nected locations and transitions by which drugs become digital. 
 The research method is to ‘follow the drug’ and thereby map processes of digitalization 
 and transition that accumulate a drug’s digital materiality. Our interest is the drug as     
(digital) artefact set in the context of its use. We start from the factory where a
   product is made and follow it into the clinic, into and out of bodies, and on
  wards as consequence or outcome. As we follow a drug we see
digitalization occurring in dierent settings – what we term 
‘episodes of  digitalization’. 
  The word episode is chosen to reect that drugs become  
  digital cumulatively through multiple transitions occur
  ring in dierent places and times.
  The 5 episodes under study are: anti counterfeiting;
  hospital prescribing and administration; patient
 centred medicine; drug safety (pharmacovigilance) and 
  research data service (big data).
 Each episode reects a new entanglement in the relation-
 ship between material and virtual aspects and between
   medicinal product/artefact (drug) and medicinal practice
  (medicine).
  
 Episodes of digitalization, for example a hospital doctor pre
 scribing using a computer, or a secure bar code being read to 
 prevent counterfeiting, can be described in terms of: digitization 
(data that moves from analog to digital form), datacation 
(accumulation of data and its multiple repurposing), and agency
migration (agency moving to the digital).
 Episodes are situations in which a drug’s therapeutic value is generat-
ed, realized and captured through digital means. We use the concept of 
a business model as a way of expressing a value architecture but we 
apply the concept not to the rm, but to the drug and to the value architec-
ture that it embodies and which is signicantly inuenced by digitalization. 
 Thus we seek  the healthcare logic of a specic practice, the value proposition it 
makes and to whom and the mobilization of resources and establishment of processes that 
it requires [3]. 
Digital Drugs: noun, pl., 
drugs that are dependent on and substantially constituted by multiple digital rep-
resentations and connections, and whose use and eectiveness is strongly mediated 
through digital means [1]
Medicines and Drugs are hybrids, part active molecule, part delivery system, 
part packaging and instructions, and embody protocols of use and aord 
work practices. They are also becoming in part digital – they are digitiz-
ing [2]. Their agency as artefacts (their material agency), in particlar 
their therapeutic potential, draws on digitised data and is
 applied through digitalised protocols.
From the supply chain, through clinical work and pa-
tients’ bodies, to post-use data repositories and in 
structures of regulation, to follow a drug is to tell a 
story of material artefacts (devices, objects) and of 
chemical actions in biological milieu. But it is also a 
story of digital materiality and digital agency.
As a hybrid digital artefact a drug is constituted 
within, and an expression of, multiple digital reresen- 
tations and inter-connections. From the in-silico scie 
nce of drug discovery, and testing procedures of
randomised control trials, a drug is embodied as digital 
data.
And the digital sedimentations continue once a drug be-
comes a licensed product and moves to manufacture and 
then use. The people and groups who work with and use 
drugs (e.g. of us) are drawn in to the digit al sphere and shape 
new practices of medicines use, individually and system wide.
In this way digitalization implies new and novel architectures of 
value creation, realization and capture – new business models. 
These are expressed in recongurations of the socio-technical and 
economic context of medicines within healthcare; as value proposi-
tions, as products and increasingly services, as therapeutic agents, as 
the locus of innovation and as new forms of regulation.
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